- Home
- CHSCL vs CRNX Comparison
CHSCL vs CRNX Comparison
Compare CHSCL & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHSCL
- CRNX
- Stock Information
- Founded
- CHSCL N/A
- CRNX 2008
- Country
- CHSCL United States
- CRNX United States
- Employees
- CHSCL N/A
- CRNX N/A
- Industry
- CHSCL Farming/Seeds/Milling
- CRNX Biotechnology: Pharmaceutical Preparations
- Sector
- CHSCL Industrials
- CRNX Health Care
- Exchange
- CHSCL Nasdaq
- CRNX Nasdaq
- Market Cap
- CHSCL N/A
- CRNX 2.8B
- IPO Year
- CHSCL N/A
- CRNX 2018
- Fundamental
- Price
- CHSCL $25.47
- CRNX $30.00
- Analyst Decision
- CHSCL
- CRNX Strong Buy
- Analyst Count
- CHSCL 0
- CRNX 10
- Target Price
- CHSCL N/A
- CRNX $75.00
- AVG Volume (30 Days)
- CHSCL N/A
- CRNX 646.9K
- Earning Date
- CHSCL N/A
- CRNX 08-07-2025
- Dividend Yield
- CHSCL N/A
- CRNX N/A
- EPS Growth
- CHSCL N/A
- CRNX N/A
- EPS
- CHSCL N/A
- CRNX N/A
- Revenue
- CHSCL N/A
- CRNX $760,000.00
- Revenue This Year
- CHSCL N/A
- CRNX $402.12
- Revenue Next Year
- CHSCL N/A
- CRNX $770.88
- P/E Ratio
- CHSCL N/A
- CRNX N/A
- Revenue Growth
- CHSCL N/A
- CRNX N/A
- 52 Week Low
- CHSCL N/A
- CRNX $24.10
- 52 Week High
- CHSCL N/A
- CRNX $62.53
- Technical
- Relative Strength Index (RSI)
- CHSCL 45.11
- CRNX 44.17
- Support Level
- CHSCL $25.15
- CRNX $28.34
- Resistance Level
- CHSCL $25.57
- CRNX $30.01
- Average True Range (ATR)
- CHSCL 0.20
- CRNX 1.07
- MACD
- CHSCL -0.01
- CRNX -0.17
- Stochastic Oscillator
- CHSCL 48.48
- CRNX 36.41
About CHSCL CHS Inc Class B Cumulative Redeemable Preferred Stock Series 4
CHS Inc is an integrated agricultural enterprise, that provides grain, food, and energy resources to businesses and consumers. Its Energy segment produces and provides wholesale distribution of petroleum products and transportation of those products. Its Ag segment, which is the key revenue driver, purchases and processes or resells grains and oilseeds; serves as a wholesaler and retailer of crop inputs; produces and markets ethanol. Its Nitrogen Production segment consists of equity method investment in CF Nitrogen, which entitles the purchase of up to a specified quantity of granular urea and UAN annually from CF Nitrogen. Geographically, the company derives maximum revenue from North America and the rest from South America, Asia Pacific, Europe, Middle East, and Africa (EMEA).
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.